OOIR: Observatory of International Research

Papers

(The H4-Index of Neurology-Neuroimmunology & Neuroinflammation is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Complement Factor I Gene Variant as a Treatable Cause of Recurrent Aseptic Neutrophilic Meningitis	413
CLIPPERS Responsive to Cladribine as a Durable Steroid-Sparing Agent	129
COVID-19 Among Patients With Multiple Sclerosis	119
MRI Characteristics of Autoimmune Encephalitis With Autoantibodies to GABAA Receptor: A Case Series	93
A 28-Year-Old Woman With Left-Sided Weakness and Atypical MRI Lesions	89
Immune-Mediated Rippling Muscle Disease Associated With Thymoma and Anti-MURC/Cavin-4 Autoantibodies	88
Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia Gravis	84
Nodular Pachymeningitis Associated With Relapsing Polychondritis and Crohn Disease Responsive to Adalimumab and Prednisone	76
Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides	74
Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis	72
Multiple Sclerosis, Disease-Modifying Therapies, and Infections	70
Paraneoplastic AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder Associated With Teratoma	61
Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis	58
More Efficient Complement Activation by Anti–Aquaporin-4 Compared With Anti–Myelin Oligodendrocyte Glycoprotein Antibodies	58
Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom	56
Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS	55
Relapsing and Immune-Responsive Paroxysmal Jaw Clonus With Blepharospasm and Sialorrhea Associated With D2R Autoantibodies	54
Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology	53
Progressive Encephalomyelopathy in an Older Man	50
Long-term Follow-up and Muscle Imaging Findings in Brachio-Cervical Inflammatory Myopathy	49
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis	47
Vascular Involvement in Neurosarcoidosis	47
T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis	45
Neurosarcoidosis of the Cauda Equina	45
Altered CSF Albumin Quotient Links Peripheral Inflammation and Brain Damage in MS	45

Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases	41
Immune-Mediated Rippling Muscle Disease Associated With Thymoma and Anti-MURC/Cavin-4 Autoantibodies	41
Therapies in Stiff-Person Syndrome	41
Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis	41
The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis	40
CSF Neurofilament Light Chain Concentrations Predict Outcome in Bacterial Meningitis	40
Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination	39
Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment	39
Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Treated With Ocrelizumab	38
Anti-IgLON5 Disease 10 Years Later	38
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival	35